There are currently no clearly defined parameters available for therapy management, as the updated S3 guideline on the diagnosis and treatment of Crohn’s disease published last year states. This is a dilemma that raises the question of other indicators for evaluating the course of treatment. In the PROFILE study, a treatment strategy involving the early use of a biologic proved to be superior to the standard procedure in terms of steroid-free and surgery-free remission.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Trichophyton indotineae
Terbinafine-resistant dermatophytoses are on the rise in Central Europe
- Peristomal skin health
Focus on preventive care options
- Disease-modifying therapies for ATTR-CM
TTR stabilizers, gene silencing and gene scissors: where do we stand?
- Proteins in wound healing
Do special amino acids lead to success?
- HER2+ early breast cancer
DESTINY-Breast11 – neoadjuvant T-DXd without anthracyclines
- Lavender aromatherapy
Take away the fear of the dentist
- Digital dermatology: innovative project examples
AI and eHealth tools in HS care
- Mantle cell lymphoma